4502 Takeda Pharmaceuticals explanation
- Prime Market
- Nikkei 225 Stocks
- Top Issues in Nikkei 225 Contribution Ranking
- TOPIX Core30
- Japan’s No.1 pharmaceutical manufacturer
- Competitors: Daiichi Sankyo, Chugai, Eisai, Astellas
- Drug discovery and development in major therapeutic areas such as gastrointestinal and inflammatory diseases, rare diseases, plasma fractionation, oncology (cancer), neuroscience (neuropsychiatric disorders), and vaccines.
- Representative products include Entyvio, a treatment for ulcerative colitis and Crohn’s disease, and Iclusig, a treatment for chronic myeloid leukemia.
- (TAK-861), an orexin receptor agonist, and “TAK-861” orexin franchise are key to sales growth
- Strength in global expansion, especially in Europe and the U.S.
- In 2019, Takeda to acquire Ireland’s Shire for $62 billion
Fiscal period
Mar.
4502 Takeda Pharmaceuticals Sales/Profit
Fiscal year ending March 2024
Sales：4263.7 billion yen（＋5.9%）
Operating income：204 billion yen（△56.4%）
Ordinary profit：52.7 billion yen（△85.9%）
